EGFR somatic mutations in lung tumors: radon exposure and passive smoking in former- and never-smoking U.S. women.

EGFR somatic mutations in lung tumors: radon exposure and passive smoking in former- and never-smoking U.S. women.
复制标题

肺癌中的 EGFR 体细胞突变:曾经吸烟和从不吸烟的美国女性的氡暴露和被动吸烟。

DOI:
10.1158/1055-9965.epi-12-0166
复制
发表时间:
2012
期刊:
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子:
--
通讯作者:
Harris,
Harris,
中科院分区:
--
文献类型:
--
作者:
Taga,Masataka;Mechanic,LeahE;Hagiwara,Nobutoshi;Vähäkangas,KirsiH;Bennett,WilliamP;Alavanja,MichaelCR;Welsh,JudithA;Khan,MohammedA;Lee,Adam;Diasio,Robert;Edell,Eric;Bungum,Aaron;Jang,JinSung;Yang,Ping;Jen,Jin;Harris,

文献摘要

相似文献

背景:表皮生长因子受体(EGFR)酪氨酸激酶突变的肺癌患者接受EGFR抑制剂治疗后预后改善。我们假设thatEGFR突变可能与住宅氡或被动吸烟smoke.Methods:这一假设进行了调查,通过分析EGFR突变在70个肺肿瘤从人口从未和长期的前女性吸烟者从密苏里州详细的暴露评估。马约诊所从不吸烟的女性肺癌病例中也检查了与被动吸烟的关系。结果:总体而言,EGFR突变的频率为41% [95%置信区间(CI),32%-49%]。氡和被动吸烟暴露均与肺肿瘤中EGFR突变无关。结论:结果表明EGFR突变在美国从不吸烟的女性肺癌病例中很常见,EGFR突变不太可能是由于暴露于氡或被动吸烟所致。©2012 AACR。
Background:Patients with lung cancer with mutations in EGF receptor (EGFR) tyrosine kinase have improved prognosis when treated withEGFRinhibitors. We hypothesized thatEGFRmutations may be related to residential radon or passive tobacco smoke.Methods:This hypothesis was investigated by analyzingEGFRmutations in 70 lung tumors from a population of never and long-term former female smokers from Missouri with detailed exposure assessments. The relationship with passive smoking was also examined in never-smoking female lung cancer cases from the Mayo clinic.Results:Overall, the frequency ofEGFRmutation was 41% [95% confidence interval (CI), 32%–49%]. Neither radon nor passive-smoking exposure was consistently associated withEGFRmutations in lung tumors.Conclusions:The results suggest thatEGFRmutations are common in female, never-smoking lung cancer cases from the United States, andEGFRmutations are unlikely due to exposure to radon or passive smoking.Cancer Epidemiol Biomarkers Prev; 21(6); 988–92. ©2012 AACR.